{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":2,"x_thread":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"CHECKMATE 920","nct_id":"NCT02982954","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-920-nct02982954. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CHECKMATE 920","arms":[{"description":"Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%","label":"ccRCC KPS ≥ 70%","type":"EXPERIMENTAL"},{"description":"Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%","label":"Non-ccRCC, KPS ≥ 70%","type":"EXPERIMENTAL"},{"description":"Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%","label":"RCC with non-active Brain Mets, KPS ≥70%","type":"EXPERIMENTAL"},{"description":"Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%","label":"any RCC with KPS 50%-60%","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-10-06","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":211,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"}],"last_update":"2022-11-01","lead_sponsor":"Bristol-Myers Squibb","official_title":"Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)","overall_status":"COMPLETED","phases":["PHASE4"],"primary_completion_date":{"date":"2020-05-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events (IMAEs)","timeFrame":"Approximately 39 Months"},{"measure":"Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events (IMAEs)","timeFrame":"Approximately 39 Months"}],"references":[{"citation":"George DJ, Spigel DR, Gordan LN, Kochuparambil ST, Molina AM, Yorio J, Rezazadeh Kalebasty A, McKean H, Tchekmedyian N, Tykodi SS, Zhang J, Askelson M, Johansen JL, Hutson TE. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ Open. 2022 Sep 14;12(9):e058396. doi: 10.1136/bmjopen-2021-058396.","pmid":"36104138","type":"DERIVED"},{"citation":"Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844.","pmid":"35210307","type":"DERIVED"}],"start_date":{"date":"2017-01-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer","url":"https://clinicaltrials.gov/study/NCT02982954"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-920-nct02982954"}